MA26961A1 - Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose - Google Patents
Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporoseInfo
- Publication number
- MA26961A1 MA26961A1 MA27159A MA27159A MA26961A1 MA 26961 A1 MA26961 A1 MA 26961A1 MA 27159 A MA27159 A MA 27159A MA 27159 A MA27159 A MA 27159A MA 26961 A1 MA26961 A1 MA 26961A1
- Authority
- MA
- Morocco
- Prior art keywords
- bone
- loss
- receptors
- osteoporosis
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
DEPOSANT Société dite: PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 27 Novembre 2000 60/253,275 Voir en annexe le titre de l'invention et le texte de l'abrégé Agonistes sélectifs des récepteurs EP4 pour le traitement de 1'ostéoporose L'invention concerne des agonistes de prostaglandines sélectives des récepteurs EP4, de formule (I), dans laquelle R2, X, Z et Q répondent aux définitions figurant dans le présent mémoire. La présente invention concerne également des compositions pharmaceutiques contenant ces composés. La présente invention concerne également des méthodes de traitement d'affections qui comportent une faible masse osseuse, en particulier 1'ostéoporose, la fragilité, une fracture ostéoporotique, un défaut osseux, la perte de tissu osseux idiopathique de l'enfant, une perte d'os alvéolaire, une perte d'os mandibulaire, une fracture d'un os, une ostéotomie, une perte de tissu osseux associée à la périodontite ou une incarnation prostétique, chez un mammifère, comprenant l'administration de ces composés.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25327500P | 2000-11-27 | 2000-11-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA26961A1 true MA26961A1 (fr) | 2004-12-20 |
Family
ID=22959588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA27159A MA26961A1 (fr) | 2000-11-27 | 2003-05-13 | Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose |
Country Status (41)
Country | Link |
---|---|
US (3) | US6552067B2 (fr) |
EP (1) | EP1339678B1 (fr) |
JP (2) | JP3984164B2 (fr) |
KR (1) | KR20030053063A (fr) |
CN (1) | CN1476429A (fr) |
AR (1) | AR035074A1 (fr) |
AT (1) | ATE374182T1 (fr) |
AU (1) | AU2002210848A1 (fr) |
BG (1) | BG107697A (fr) |
BR (1) | BR0115687A (fr) |
CA (1) | CA2429850C (fr) |
CY (1) | CY1106976T1 (fr) |
CZ (1) | CZ20031257A3 (fr) |
DE (1) | DE60130675T2 (fr) |
DK (1) | DK1339678T3 (fr) |
EA (1) | EA200300379A1 (fr) |
EC (1) | ECSP034623A (fr) |
EE (1) | EE200300246A (fr) |
ES (1) | ES2291361T3 (fr) |
GT (2) | GT200100238A (fr) |
HN (1) | HN2001000266A (fr) |
HU (1) | HUP0400807A2 (fr) |
IL (1) | IL155368A0 (fr) |
IS (1) | IS6775A (fr) |
MA (1) | MA26961A1 (fr) |
MX (1) | MXPA03004623A (fr) |
NO (1) | NO20032360L (fr) |
NZ (1) | NZ525164A (fr) |
OA (1) | OA12533A (fr) |
PA (1) | PA8533901A1 (fr) |
PE (1) | PE20020637A1 (fr) |
PL (1) | PL362030A1 (fr) |
PT (1) | PT1339678E (fr) |
SI (1) | SI1339678T1 (fr) |
SK (1) | SK5562003A3 (fr) |
SV (1) | SV2003000746A (fr) |
TN (1) | TNSN01166A1 (fr) |
TW (1) | TW200424170A (fr) |
UY (1) | UY27038A1 (fr) |
WO (1) | WO2002042268A2 (fr) |
ZA (1) | ZA200302803B (fr) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
RU2288913C2 (ru) | 2001-07-16 | 2006-12-10 | Ф.Хоффманн-Ля Рош Аг | Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4 |
AU2002328338C1 (en) | 2001-07-16 | 2009-01-08 | Ono Pharmaceutical Co., Ltd | 2 pyrrolidone derivatives as prostanoid agonists |
MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
MXPA04008596A (es) | 2002-03-05 | 2004-12-06 | Ono Pharmaceutical Co | Compuestos derivados de 8-azaprostaglandina y farmacos que contienen los compuestos como ingrediente activo. |
EP1487437B1 (fr) * | 2002-03-18 | 2006-08-16 | Pfizer Products Inc. | Utilisation d'agonistes selectifs du recepteur ep4 pour le traitement de maladies |
MXPA04009036A (es) * | 2002-03-18 | 2005-01-25 | Pfizer Prod Inc | Uso de agonistas del receptor ep4 selectivos para el tratamiento de la insuficiencia hepatica, perdida de permeabilidad del ductus arterioso, glaucoma o hipertension ocular. |
US6573294B1 (en) | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
WO2003103664A1 (fr) * | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | Derives d'imidazolidine-2-one disubstitues en 1,5 utiles en tant qu'agonistes du recepteur ep4 dans le traitement de troubles oculaires et de maladies osseuses |
WO2003103772A1 (fr) | 2002-06-06 | 2003-12-18 | Merck Frosst Canada & Co. | Derives de pyrrolid-2-one 1,5 disubstitues utilises comme agonistes de recepteur ep4 pour traiter des maladies oculaires telles que le glaucome |
EP1556347A4 (fr) * | 2002-06-10 | 2006-08-09 | Applied Research Systems | Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation |
GB0219143D0 (en) * | 2002-08-16 | 2002-09-25 | Univ Leicester | Modified tailed oligonucleotides |
ES2393321T3 (es) | 2002-10-10 | 2012-12-20 | Ono Pharmaceutical Co., Ltd. | Promotores de la producción de factores de reparación endógenos |
AU2003275838A1 (en) * | 2002-10-25 | 2004-05-13 | Beunard, Jean-Luc | Pyrrolidin-2-on derivatives as ep4 receptor agonists |
US7196082B2 (en) | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2004043354A2 (fr) | 2002-11-08 | 2004-05-27 | Merck & Co., Inc. | Compositions ophtalmiques pour traiter l'hypertension oculaire |
US7053085B2 (en) * | 2003-03-26 | 2006-05-30 | Merck & Co. Inc. | EP4 receptor agonist, compositions and methods thereof |
CA2511255C (fr) * | 2003-01-10 | 2009-04-07 | F. Hoffmann-La Roche Ag | Derives de 2-piperidone agonistes de la prostaglandine |
JP4582456B2 (ja) * | 2003-01-21 | 2010-11-17 | 小野薬品工業株式会社 | 8−アザプロスタグランジン誘導体およびその医薬用途 |
JP4662926B2 (ja) | 2003-03-03 | 2011-03-30 | メルク セローノ ソシエテ アノニム | プロスタグランジン作動薬としてのγ−ラクタム誘導体 |
US6734206B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 3-oxa-8-azaprostaglandin analogs as agents for lowering intraocular pressure |
US6734201B1 (en) | 2003-06-02 | 2004-05-11 | Allergan, Inc. | 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents |
WO2005012232A2 (fr) | 2003-07-18 | 2005-02-10 | Applied Research Systems Ars Holding N.V. | Derives d'hydrazides constituant des modulateurs des recepteurs de la prostaglandine |
US7034051B2 (en) * | 2003-08-28 | 2006-04-25 | Adolor Corporation | Fused bicyclic carboxamide derivatives and methods of their use |
US7576122B2 (en) | 2003-09-02 | 2009-08-18 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
KR20060090801A (ko) | 2003-09-04 | 2006-08-16 | 머크 앤드 캄파니 인코포레이티드 | 고안압증 치료용 안용 조성물 |
JP2007504236A (ja) | 2003-09-04 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼用組成物 |
WO2005027931A1 (fr) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Compositions pharmaceutiques et methodes de traitement consistant en des associations d'un derive de la 2-alkylidene-19-nor-vitamine d et d'un agoniste selectif de ep2 ou ep4 |
BRPI0417621A (pt) * | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea |
US7169807B2 (en) * | 2004-04-09 | 2007-01-30 | Allergan, Inc. | 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists |
JP2008507521A (ja) | 2004-07-20 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症を治療するための眼科用組成物 |
JP4893999B2 (ja) * | 2004-10-22 | 2012-03-07 | 小野薬品工業株式会社 | 吸入用医薬組成物 |
US20080132543A1 (en) * | 2004-10-26 | 2008-06-05 | Wha Bin Im | Therapeutic and Delivery Methods of Prostaglandin Ep4, Agonists |
WO2006052630A1 (fr) * | 2004-11-04 | 2006-05-18 | Allergan, Inc. | Composes therapeutiques de piperidone substituee |
CA2586752A1 (fr) * | 2004-11-08 | 2006-05-18 | Allergan, Inc. | Pyrrolidones substituees en tant qu'agonistes d'ep4 |
US7101906B2 (en) * | 2004-11-16 | 2006-09-05 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
US7183324B2 (en) | 2004-11-23 | 2007-02-27 | Allergan, Inc. | 2,3,4-substituted cyclopentanones as therapeutic agents |
KR100890490B1 (ko) * | 2005-01-27 | 2009-03-26 | 아사히 가세이 파마 가부시키가이샤 | 헤테로 6원환 화합물 및 그의 용도 |
US7531533B2 (en) | 2005-01-27 | 2009-05-12 | Asahi Kasei Pharma Corporation | 6-Membered heterocyclic compound and use thereof |
WO2006121708A1 (fr) * | 2005-05-06 | 2006-11-16 | Allergan, Inc. | Beta-lactamines substituees ainsi que leur utilisation en medecine |
US7772392B2 (en) | 2005-05-06 | 2010-08-10 | Allergan, Inc. | Therapeutic substituted β-lactams |
US7893107B2 (en) * | 2005-11-30 | 2011-02-22 | Allergan, Inc. | Therapeutic methods using prostaglandin EP4 agonist components |
KR100598678B1 (ko) * | 2006-02-15 | 2006-07-19 | (주)아이앤씨 | 수직형 대형 폐기물 파쇄기 |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
EP2094839B1 (fr) | 2006-12-08 | 2020-02-05 | University of Rochester | Expansion de cellules souches hématopoïétiques |
BRPI0721067A2 (pt) * | 2006-12-18 | 2014-02-25 | Allergan Inc | Métodos e composições para tratar distúrbios gastrointestinais. |
KR20100016299A (ko) | 2007-05-08 | 2010-02-12 | 고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 | Ep4 아고니스트를 함유하여 이루어지는 세포 상해성 t 세포의 활성화제 |
WO2008144623A1 (fr) * | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Lactames cycliques destinés au traitement du glaucome ou de la pression intraoculaire élevée |
US8063033B2 (en) * | 2008-01-18 | 2011-11-22 | Allergan, Inc. | Therapeutic beta-lactams |
US8202855B2 (en) | 2008-03-04 | 2012-06-19 | Allergan, Inc | Substituted beta-lactams |
US7705001B2 (en) * | 2008-03-18 | 2010-04-27 | Allergan, Inc | Therapeutic substituted gamma lactams |
EP2320906B1 (fr) * | 2008-08-14 | 2016-02-24 | Beta Pharma Canada Inc. | Dérivés d amides hétérocycliques en tant qu antagonistes du récepteur ep4 |
WO2010116270A1 (fr) | 2009-04-10 | 2010-10-14 | Pfizer Inc. | Agonistes de ep2/4 |
US20120190637A1 (en) | 2009-10-14 | 2012-07-26 | Gemmus Pharma, Inc. | Combination therapy treatment for viral infections |
ES2593229T3 (es) * | 2010-03-08 | 2016-12-07 | Kaken Pharmaceutical Co., Ltd. | Nuevo agonista de EP4 |
CA2738045C (fr) | 2010-05-28 | 2019-02-19 | Simon Fraser University | Composes conjugues, leurs procedes de fabrication et leurs utilisations |
EP2397141A1 (fr) * | 2010-06-16 | 2011-12-21 | LEK Pharmaceuticals d.d. | Procédé pour la synthèse d'acides aminés beta et leurs dérivés |
US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
EP2675491A2 (fr) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions et procédés améliorés de remplacement de tissu mou |
WO2013105997A2 (fr) | 2011-02-23 | 2013-07-18 | Allergan, Inc. | Compositions et procédés de remplacement de tissu mou améliorés |
WO2013123272A1 (fr) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions et procédés perfectionnés de remplacement de tissu mou |
EP2814526B1 (fr) | 2012-02-16 | 2016-11-02 | Allergan, Inc. | Compositions et procédés perfectionnés de remplacement de tissu mou |
EP2814527A1 (fr) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions et procédés perfectionnés de remplacement de tissu mou |
WO2013123270A1 (fr) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions et procédés perfectionnés de remplacement de tissu mou |
KR102151578B1 (ko) * | 2012-07-19 | 2020-09-03 | 카이맨 케미칼 컴파니 인코포레이티드 | Ep4-매개의 골 관련 질병 및 질환을 위한 디플루오로락탐 조성물 |
JP6400479B2 (ja) | 2012-10-29 | 2018-10-03 | 株式会社カルディオ | 肺疾患特異的治療剤 |
JP6368351B2 (ja) | 2013-03-15 | 2018-08-01 | ケイマン ケミカル カンパニー, インコーポレーテッド | ジフルオロラクタムアナログを合成する方法 |
CA2906134A1 (fr) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Composes de lactame en tant qu'antagonistes selectifs du recepteur ep4 pour une utilisation dans le traitement de maladies et d'etats medies par l'ep4 |
US9676712B2 (en) | 2013-03-15 | 2017-06-13 | Cayman Chemical Company, Inc. | Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions |
JP2016527006A (ja) | 2013-07-19 | 2016-09-08 | ケイマン ケミカル カンパニー, インコーポレーテッド | 骨成長を促進するための方法、システム、及び組成物 |
NZ717739A (en) | 2013-08-09 | 2023-12-22 | Ardelyx Inc | Compounds and methods for inhibiting phosphate transport |
WO2015056504A1 (fr) | 2013-10-15 | 2015-04-23 | 小野薬品工業株式会社 | Greffe d'endoprothèse à élution de médicament |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
BR112016028614A8 (pt) | 2014-06-06 | 2021-04-06 | Allergan Inc | novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso |
US9540357B1 (en) | 2014-07-31 | 2017-01-10 | Allergan, Inc. | 15-aryl prostaglandins as EP4 agonists, and methods of use thereof |
EP3307747A4 (fr) | 2015-06-12 | 2019-02-27 | Simon Fraser University | Composés agoniste d'ep4-bisphosphonate à liaison amide et leurs utilisations |
CN107011377B (zh) * | 2017-05-03 | 2019-02-26 | 南通书创药业科技有限公司 | 一种β-羰基磷酸酯的制备方法 |
BR112020012405A2 (pt) | 2017-12-25 | 2020-11-24 | Asahi Kasei Pharma Corporation | composto cíclico de 6 membros contendo nitrogênio. |
US20200368223A1 (en) | 2019-05-21 | 2020-11-26 | Ardelyx, Inc. | Methods for inhibiting phosphate transport |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1158163A (en) | 1966-06-15 | 1969-07-16 | Berk Ltd | Improvements in or relating to Polymer Compositions |
ZA72645B (en) * | 1971-03-05 | 1972-11-29 | Upjohn Co | Prostaglandin analogs |
DE2346706A1 (de) * | 1973-09-17 | 1975-04-03 | Hoechst Ag | Neue, nicht natuerlich vorkommende analoga von prostansaeuren und verfahren zu ihrer herstellung |
US3975399A (en) | 1974-08-06 | 1976-08-17 | E. I. Du Pont De Nemours And Company | 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones |
US4113873A (en) | 1975-04-26 | 1978-09-12 | Tanabe Seiyaku Co. Ltd. | 8-azaprostanoic acid derivatives |
NL7604330A (nl) | 1975-04-28 | 1976-11-01 | Syntex Inc | Werkwijze voor de bereiding van 8-azaprostaan- zuurderivaten. |
DE2528664A1 (de) | 1975-06-27 | 1977-01-13 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
IL49325A (en) | 1976-03-31 | 1979-11-30 | Labaz | 8-aza-11-deoxy-pge1 derivatives,their preparation and pharmaceutical compositions containing them |
DE2619638A1 (de) | 1976-05-04 | 1977-11-17 | Hoechst Ag | Pyrrolidone und verfahren zu ihrer herstellung |
US4177346A (en) * | 1976-08-06 | 1979-12-04 | Pfizer Inc. | 1,5-Disubstituted-2-pyrrolidones |
CA1077948A (fr) * | 1976-08-06 | 1980-05-20 | Albin J. Nelson | Production de 2-pyrrolidones disubstituees en 1,5 |
US4320136A (en) | 1980-08-11 | 1982-03-16 | E. I. Du Pont De Nemours And Company | 8-Aza-16,16-difluoroprostanoids |
US4456613A (en) | 1982-12-27 | 1984-06-26 | E. I. Du Pont De Nemours And Company | 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof |
TW288010B (fr) | 1992-03-05 | 1996-10-11 | Pfizer | |
SE9302334D0 (sv) | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
ZA944647B (en) | 1993-07-06 | 1995-01-06 | Astra Ab | Novel (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclcl)methylamine derivatives |
US5955481A (en) | 1994-03-28 | 1999-09-21 | Nissan Chemical Industries, Ltd. | Pyridine type thiazolidines |
TW420669B (en) | 1994-03-28 | 2001-02-01 | Nissan Chemical Ind Ltd | Pyridine type thiazolidines |
US5703108A (en) * | 1996-02-28 | 1997-12-30 | Pfizer Inc. | Bone deposition by certain prostaglandin agonists |
WO2000021532A1 (fr) | 1998-10-15 | 2000-04-20 | Merck & Co., Inc. | Inhibition de la resorption osseuse |
JP2002527400A (ja) * | 1998-10-15 | 2002-08-27 | メルク エンド カムパニー インコーポレーテッド | 骨形成刺激方法 |
TR200201643T2 (tr) * | 1999-12-22 | 2002-11-21 | Pfizer Products Inc. | Osteoporoz tedavisi için EP4 reseptörünü seçici agonistler. |
DE60120007T2 (de) * | 2000-01-31 | 2006-11-16 | Pfizer Products Inc., Groton | Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz |
US20010056060A1 (en) * | 2000-02-07 | 2001-12-27 | Cameron Kimberly O. | Treatment of osteoporsis with EP2/EP4 receptor selective agonists |
NZ525164A (en) * | 2000-11-27 | 2005-04-29 | Pfizer Prod Inc | EP4 receptor selective agonists in the treatment of osteoporosis |
US6573294B1 (en) * | 2002-05-14 | 2003-06-03 | Allergan, Inc. | 8-azaprostaglandin analogs as agents for lowering intraocular pressure |
-
2001
- 2001-11-05 NZ NZ525164A patent/NZ525164A/en unknown
- 2001-11-05 AU AU2002210848A patent/AU2002210848A1/en not_active Abandoned
- 2001-11-05 BR BR0115687-0A patent/BR0115687A/pt not_active Withdrawn
- 2001-11-05 SK SK556-2003A patent/SK5562003A3/sk not_active Application Discontinuation
- 2001-11-05 HU HU0400807A patent/HUP0400807A2/hu unknown
- 2001-11-05 ES ES01978757T patent/ES2291361T3/es not_active Expired - Lifetime
- 2001-11-05 EP EP01978757A patent/EP1339678B1/fr not_active Expired - Lifetime
- 2001-11-05 EE EEP200300246A patent/EE200300246A/xx unknown
- 2001-11-05 CZ CZ20031257A patent/CZ20031257A3/cs unknown
- 2001-11-05 DK DK01978757T patent/DK1339678T3/da active
- 2001-11-05 IL IL15536801A patent/IL155368A0/xx unknown
- 2001-11-05 DE DE60130675T patent/DE60130675T2/de not_active Expired - Fee Related
- 2001-11-05 SI SI200130776T patent/SI1339678T1/sl unknown
- 2001-11-05 CN CNA018194877A patent/CN1476429A/zh active Pending
- 2001-11-05 JP JP2002544404A patent/JP3984164B2/ja not_active Expired - Lifetime
- 2001-11-05 EA EA200300379A patent/EA200300379A1/ru unknown
- 2001-11-05 CA CA002429850A patent/CA2429850C/fr not_active Expired - Fee Related
- 2001-11-05 KR KR10-2003-7007109A patent/KR20030053063A/ko not_active Application Discontinuation
- 2001-11-05 MX MXPA03004623A patent/MXPA03004623A/es active IP Right Grant
- 2001-11-05 OA OA1200300141A patent/OA12533A/en unknown
- 2001-11-05 AT AT01978757T patent/ATE374182T1/de not_active IP Right Cessation
- 2001-11-05 PT PT01978757T patent/PT1339678E/pt unknown
- 2001-11-05 WO PCT/IB2001/002073 patent/WO2002042268A2/fr active IP Right Grant
- 2001-11-05 PL PL01362030A patent/PL362030A1/xx not_active Application Discontinuation
- 2001-11-21 US US09/990,556 patent/US6552067B2/en not_active Expired - Fee Related
- 2001-11-23 UY UY27038A patent/UY27038A1/es not_active Application Discontinuation
- 2001-11-23 HN HN2001000266A patent/HN2001000266A/es unknown
- 2001-11-26 TN TNTNSN01166A patent/TNSN01166A1/fr unknown
- 2001-11-26 SV SV2001000746A patent/SV2003000746A/es unknown
- 2001-11-26 PE PE2001001180A patent/PE20020637A1/es not_active Application Discontinuation
- 2001-11-26 TW TW093115078A patent/TW200424170A/zh unknown
- 2001-11-26 AR ARP010105489A patent/AR035074A1/es unknown
- 2001-11-27 GT GT200100238A patent/GT200100238A/es unknown
- 2001-11-27 PA PA20018533901A patent/PA8533901A1/es unknown
- 2001-11-27 GT GT200100238AK patent/GT200100238AA/es unknown
-
2002
- 2002-12-20 US US10/326,366 patent/US6747054B2/en not_active Expired - Fee Related
-
2003
- 2003-04-03 BG BG107697A patent/BG107697A/xx unknown
- 2003-04-10 IS IS6775A patent/IS6775A/is unknown
- 2003-04-10 ZA ZA200302803A patent/ZA200302803B/en unknown
- 2003-05-13 MA MA27159A patent/MA26961A1/fr unknown
- 2003-05-26 NO NO20032360A patent/NO20032360L/no not_active Application Discontinuation
- 2003-05-27 EC EC2003004623A patent/ECSP034623A/es unknown
- 2003-09-23 US US10/668,633 patent/US7192979B2/en not_active Expired - Fee Related
-
2007
- 2007-05-11 JP JP2007127062A patent/JP2007197467A/ja active Pending
- 2007-11-06 CY CY20071101420T patent/CY1106976T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA26961A1 (fr) | Agonistes selectifs des recepteurs ep4 pour le traitement de l'osteoporose | |
AP2001002357A0 (en) | EP4 receptor selective agonists in the treatment of osteoporosis. | |
MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
MA27774A1 (fr) | Inhibiteurs de phosphatidylinositol 3-kinase | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
MA27009A1 (fr) | Derives de pyrazole pour le traitement d'une infection par le vih | |
ATE286500T1 (de) | 1,2,3,4-tetrahydroisochinolin-derivate | |
MA26873A1 (fr) | Derives de purine | |
CA2407100A1 (fr) | 1-aroyle-piperidinyle benzamidines | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
MA27347A1 (fr) | Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese | |
MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
MA30296B1 (fr) | Nouvelles amines | |
FR2918571B1 (fr) | Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales | |
MA27017A1 (fr) | Procede pour la production d'une composition pharmaceutique a faible dose ayant une distribution et activite medicamenteuses uniformes | |
MA27852A1 (fr) | Derives de 1-(alkylaminoalkyl-pyrolidin-/piperidinyl)-2,2-diphenylacetamide utilises comme antagonistes du recepteur muscarinique | |
MA26701A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT. | |
MA30292B1 (fr) | Amines primaires comme inhibiteurs de la renine | |
ATE386523T1 (de) | Synergistische pharmazeutische zusammensetzungen zur behandlung bzw. prophylaxe von diabetes | |
DE69919349D1 (de) | Piperidinyl- und n-amidinopiperidinyl-derivate | |
MA27435A1 (fr) | DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH | |
MA30924B1 (fr) | Analogues de pyrazoles | |
UA83870C2 (ru) | Замещенные бицикло[3.1.1]гептаном производные бензимидазолона и хиназолинона как агонисты человеческих рецепторов orl1 | |
IL149544A0 (en) | N-ACYLPYRROLIDIN-2-YLALKYLBENZAMIDINE DERIVATIVES AS INHIBITORS OF FACTOR Xa | |
JP2022077010A (ja) | 細菌の歯肉上皮細胞への侵入抑制剤及び感染抑制剤 |